Navigation Links
NanoPass Makes its MicronJet Technology Available to Increase Global Supply of Pandemic Influenza Vaccines
Date:8/13/2009

NES ZIONA, Israel, August 13 /PRNewswire/ -- Following the World Health Organization (WHO) declaration of a swine flu pandemic,[1] NanoPass Technologies Ltd. (NanoPass) announced today that it has successfully developed a microneedle-based injection device that could dramatically enhance both the effectiveness and supply of pandemic flu vaccines.

"As declared by WHO on June 11th, 2009", said Dr Yotam Levin, the Company's CEO, "the novel A H1N1 influenza has become a phase 6 global pandemic. There is an imminent need of developing countries, as well as that of many developed countries, for an adequate supply of pandemic flu vaccines. Since global capacity is limited and production yield is reported to be low, novel approaches for vaccine enhancement are of great need." Dr Ofer Sharon, the Company's Medical Director added, "NanoPass has proven in a randomized clinical trial, recently published in Vaccine,[2] that it can reduce the dose of a seasonal flu vaccine by 80% while preserving its efficacy. This effect is thought to be achieved by targeting the potent specialized immune cells that reside in the skin. This means that health authorities can use the same amount of vaccine they have sourced, to vaccinate at least double, if not triple, the number of subjects, with the same vaccine purchase." NanoPass is designing clinical studies to demonstrate this significant effect for swine H1N1.

The major global public threat posed by the new H1N1 flu strain demands close coordination among vaccine manufacturers, governments, technology developers and global health authorities to manage the supply of vaccines and to ensure there are enough doses for everyone.

About NanoPass's MicronJet Device

MicronJet is a microneedle-based device for intradermal delivery of vaccines. The device allows for consistent, reliable, and simple delivery of the vaccine directly into the skin. It has been shown in multiple clinical trials,[3,4] that injecting a seasonal influenza vaccine directly into the skin harnesses this very potent immune organ, and allows for both the reduction of the dose required for the same immune response ("dose sparing"), as well as the ability to actually potentiate this response, with the use of equivalent doses ("increased immunogenicity").[5]

This approach is being tested for a variety of major diseases that do not yet have an effective vaccine, such as malaria, HIV and tuberculosis.

NanoPass - Transforming device innovation into global health solutions

NanoPass, founded by Dr Shuki Yeshurun, is an Israeli-based private company developing an innovative delivery device for the enhancement of vaccines and other large molecules. The Company has proven efficacy and safety in multiple applications including seasonal flu, insulin delivery and lidocaine for local anesthesia. MicronJet is approved for marketing in the EU (please see http://www.nanopass.com for more information), and is about to be registered in additional markets. The MicronJet is approved for use by health care professionals for intradermal delivery of drugs and medicinal products that are approved for intradermal delivery.

    References
    [1http://www.who.int/mediacentre/news/statements/2009/
       h1n1_pandemic_phase6_20090611/en/index.html

    (Due to the length of this URL, it may be necessary to copy and paste
     this hyperlink into your Internet browser's URL address field. Remove
     the space if one exists.)

    [2] Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon
        O and Levin Y. Safety and efficacy of a novel microneedle device
        for dose sparing intradermal influenza vaccination in healthy adults.
        Vaccine. 2009 Jan 14;27(3):454-9.

    [3] Belshe RB, Newman, FK et al. Serum Antibody Responses after
        Intradermal Vaccination against Influenza. N Engl J Med
        2004;351:2286-94.

    [4] Kenney RT, Frech SA et al. Dose sparing with intradermal injection of
        influenza vaccine. N Engl J Med. 2004 Nov 25;351(22):2295-301. Epub
        2004 Nov 3.

    [5] Holland D, Booy R et al. Intradermal influenza vaccine administered
        using a new microinjection system produces superior immunogenicity in
        elderly adults: a randomized controlled trial. JID 2008; 198:650-58.

Contact: Yotam Levin: +972-8-9313099 or +972-523-392727 or yotam@nanopass.com


'/>"/>
SOURCE NanoPass Technologies LTD.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Smart Technology Makes Patient Data Collection Easier, More Efficient
2. WeissComm Partners Makes 10 New Hires as It Wins New Accounts and Grows Existing Business
3. Independence Blue Cross Makes Music for Members Ears
4. A Place for Mom COO Makes Seattles 40 Under 40 List
5. Sesame Street Exhibition Makes Texas Premier at The Health Museum
6. Study makes progress in zoning in on biomarkers for better colon cancer treatment
7. New Online Tool Makes Enrollment in Blue Cross of California Easier
8. 1-800-PACK-RAT Makes a Splash During Annual Walk for Hope
9. Eye on Safety Makes Halloween Less Scary
10. An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal
11. Michigan State Medical Society Foundation Makes A Difference by Assisting Those in Crisis Shelters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... ... Overseer at The House of Yahweh, has written a new article this week meant to ... stop cancer. Yisrayl says there are too many suffering and dying from the disease to ... pay close attention and take action. The Pastor says that the root cause of all ...
(Date:5/6/2016)... MOOREFIELD, W.V. (PRWEB) , ... May 06, 2016 , ... ... by WestBow Press) shares accounts of dying patients who have allowed those holding vigil ... June E. Kuykendall, RN, BSN, CHPN, hopes to help readers spiritually and practically gain ...
(Date:5/5/2016)... PA (PRWEB) , ... May 05, 2016 , ... ... on long-acting injectables (LAIs), today announced a development collaboration with the ... to treat serious mental disorders such as schizophrenia. , LAI medicines can offer ...
(Date:5/5/2016)... ... May 05, 2016 , ... TLC Laser Eye Centers announced today that ... eye center will now be called “Gordon Schanzlin New Vision Institute, a TLC Laser ... the full-service facility to ensure that patients continue to receive the highest quality of ...
(Date:5/5/2016)... ... 2016 , ... LELO has discovered many people are insecure about ... via email, social media and on the Volonté blog seeking advice about how to ... ‘normal’ or ‘correct’?” , While some methods are more common than others, there is ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... May 5, 2016  Diagnostic imaging has been ... to concerns that these tests cause health care costs to ... imaging, as well as the adoption of new ... medical peripherals that help health care providers cut costs, while ... medical imaging is a renowned authorized reseller of the ...
(Date:5/5/2016)... 5, 2016 Research ... "Europe Thalassaemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... and Competitive Landscape Highlights - 2016, provides ... epidemiology, Thalassaemia market valuations and forecast, Thalassaemia ...
(Date:5/4/2016)... NESS ZIONA, Israel , May ... BVXV, TASE: BVXV) announced today that BiondVax,s CEO, Dr. ... 2016 conference in New York City . ... presenting at 10:30am at Pioneers 2016, a conference presented by ... New York Palace Hotel. The BiondVax presentation that ...
Breaking Medicine Technology: